Skip to main content
MedPathMedPath Home
Clinical Trials/DRKS00003349
DRKS00003349
Completed
Phase 2

FTO-genotype dependent weight reduction under treatment with bromocriptine in obese patients - GAB-FTO

niversität zu Köln0 sites47 target enrollmentOctober 4, 2012
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsadipositasE66.0Obesity due to excess calories

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
adipositas
Sponsor
niversität zu Köln
Enrollment
47
Status
Completed
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 4, 2012
End Date
June 3, 2015
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
niversität zu Köln

Eligibility Criteria

Inclusion Criteria

  • •1\.BMI \= 30 kg/m2
  • •2\.Age \= 18 years
  • •3\.Existence of written informed consent

Exclusion Criteria

  • •1\.Known intolerance to bromocriptine or other components oft he IMP
  • •2\.Diabetes mellitus type 1 and type 2 (excluded by measurement of HbA1c at the screening visit, exclusion with HbA1c \> 6,5%)
  • •3\.Hypo\- or hyperthyroidism (excluded by measurement of TSH, fT3 and fT4\)
  • •4\.Pregnancy or lactation
  • •5\.Known uncontrolled arterial hypertension (systolic blood pressure \> 160mmHg or diastolic blood pressure \> 100mmHg; both under antihypertensive treatment)
  • •6\.Known coronary heart disease
  • •7\.Known peripheral artery occlusive disease (PAOD)
  • •8\.Known existence of one of the following hepatic diseases: acute or chronic viral hepatitis, cirrhosis oft he liver
  • •9\.Known existence of renal insufficiency, according to a glomerular filtration rate (GFR) \= 59 ml/min (calculation according to the MDRD formula)
  • •10\.Known existence of Parkinson’s Disease

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
FTO-genotype dependent weight reduction under treatment with bromocriptin in obesityObesity with BMI = 30kg/m²Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
EUCTR2011-005628-16-DEniversity of Cologne
Completed
Not Applicable
A study examining the importance of genetic variation for the ability of severely ill anorectic women to gain weight during three yearsAnorexia nervosaMental and Behavioural Disorders
ISRCTN76310580Sahlgrenska University Hospital25
Recruiting
Not Applicable
Effect of the FTO-genotypes on the differences in energy expenditure after cold exposureThe FREECE studyhealthy subjects
DRKS00010489ehrstuhl für ErnährungsmedizinZIEL ErnährungsmedizinTU München120
Not yet recruiting
Not Applicable
The role of FTO Gene Variants on Metabolic Flexibility and Training Adaptations following a 12 Week High Intensity Exercise InterventioMetabolic FlexibilityOverweight and ObesityHuman Genetics and Inherited Disorders - Other human genetics and inherited disordersPhysical Medicine / Rehabilitation - Other physical medicine / rehabilitationDiet and Nutrition - Obesity
ACTRN12613000059763Victoria University20
Completed
Not Applicable
FTO Gene Variants and Diet in ObesityObesityDiet HabitGenetic Predisposition
NCT04205318Hacettepe University400